We thank Gagner and Shamamian for their interesting comments. For the sake of brevity, we had not discussed in detail in our review the issue of CD45 expression in CEPs. In most clinical studies published so far in cancer or cardiovascular medicine, CEPs have been counted by flow cytometry according to the expression of CD133 or CD34, and data about CD45 expression were not available. Similarly, in many preclinical studies in mice (in which CD133 expression is usually not investigated), CD45 expression data are lacking. In our experience, the large majority of human CD133 , in our recent clinical studies in patients with breast cancer who received metronomic chemotherapy 1 we found that the total number of CD133 + progenitor cells (independently from CD45 expression, studied in detail by different gating strategies) did not correlate with the clinical outcome. We fully agree with Gagner and Shamamian that these inconclusive results probably reflect our limited understanding of CEP origin and differentiation steps in adults, and that more research is warranted in this area.
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